TAMOXIFEN AND ENDOMETRIAL CARCINOMA - ALTERATIONS IN ESTROGEN AND PROGESTERONE RECEPTORS IN UNTREATED PATIENTS AND COMBINATION HORMONAL-THERAPY IN ADVANCED NEOPLASIA
TAMOXIFEN AND ENDOMETRIAL CARCINOMA - ALTERATIONS IN ESTROGEN AND PROGESTERONE RECEPTORS IN UNTREATED PATIENTS AND COMBINATION HORMONAL-THERAPY IN ADVANCED NEOPLASIA
复制标题
DOI：
10.1016/0002-9378(84)90187-x
复制
发表时间：
1984-01-01
影响因子：
9.8
通讯作者：
WITTLIFF, JL
中科院分区：
文献类型：
--
作者：
CARLSON, JA;ALLEGRA, JC;WITTLIFF, JL
在柠檬酸他莫昔芬治疗5天前后，对以前未经治疗的子宫内膜癌患者的肿瘤进行雌激素和孕激素受体测定。在最初的活检中，25个肿瘤中有13个（52%）是孕激素受体阳性，而25个肿瘤中有21个（84%）是他莫昔芬后孕激素受体阳性。1级和2级肿瘤更有可能表现出可测量的孕酮受体的发生率增加。考虑到孕激素受体阳性的转移性子宫内膜癌比孕激素受体阴性的肿瘤对孕酮治疗更敏感，制定了他莫昔芬加孕酮治疗复发性子宫内膜癌患者的II期临床试验。然而，到目前为止，联合治疗达到的33%的总反应率并不上级标准的曲马多菌素治疗。
Estrogen and progesterone receptors were measured in tumors from patients with previously untreated endometrial carcinoma before and after a 5-day course of tamoxifen citrate. On initial biopsy, 13 of 25 tumors (52%) were progesterone receptor-positive, whereas 21 of 25 tumors (84%) were progesterone receptor-positive after tamoxifen. Grades 1 and 2 tumors were more likely to demonstrate this increased incidence of measurable progesterone receptors. Considering that progesterone receptor-positive metastatic endometrial cancer was more responsive to progestin therapy than are progesterone receptor-negative tumors, a phase II clinical trial of tamoxifen plus progestin for patients with recurrent endometrial carcinoma was instituted. Thus far, however, the 33% total response rate achieved with the combination therapy has not been superior to standard progestin therapy.